<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Many clinicians providing care and advice to patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), where the principal clinical manifestation is <z:hpo ids='HP_0001297'>stroke</z:hpo>, do so in the setting of an evidence base of mixed quality </plain></SENT>
<SENT sid="1" pm="."><plain>Indeed, systematic studies have not particularly helped the practising clinician as they have been characterised by variable criteria used to select subjects, making it impossible to extrapolate to typical clinic patients </plain></SENT>
<SENT sid="2" pm="."><plain>This has left us with a number of key questions, each of which attracts controversy in terms of patient management </plain></SENT>
<SENT sid="3" pm="."><plain>In this review, these are posed as a series of questions with the answer, or lack of one, considered after each question </plain></SENT>
<SENT sid="4" pm="."><plain>The review draws attention to the important questions that require answers for current primary and secondary prevention, as well as treatment of APS and <z:hpo ids='HP_0001297'>stroke</z:hpo>, and suggests a series of studies that are needed to clarify these issues </plain></SENT>
</text></document>